NCT07526974尚未招募3 期
A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 320
- 试验地点
- 14
- 主要终点
- Percentage of participants achieving at least a 2-grade improvement from baseline on Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) and a clinically meaningful reduction in abdominal fat.
研究概览
简要总结
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
详细描述
A total of approximately 320 adult participants with moderate or severe abdominal fat at Baseline 1 will be enrolled. Each participant will receive up to 4 treatments of allocated study drug administered subcutaneously to the abdomen, once every 4 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female, aged ≥ 18 years old.
- •Body mass index (BMI) > 18.5 and < 30 kg/m2 and body weight ≥ 50 kg.
- •Participant has moderate or severe abdominal fat as assessed by the Investigator on the CR-AFRS and by the participant on the PR-AFRS.
- •Dissatisfaction with the abdominal fat expressed by the participant using Patient Self Rating Scale (PSRS) reported by participant.
- •Participant maintained a stable lifestyle.
- •Voluntarily signs the Informed Consent Form and is physically and mentally capable of participating in the study, and willing to adhere to study procedures.
排除标准
- •Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive method, or who is currently pregnant or lactating. Male participant who is not committing to using condom consistently and refraining from sperm donation.
- •Participant who has impeded coagulation or platelet aggregation.
- •Participant has delayed wound healing or poorly controlled diabetes.
- •Participant has active malignancies or is currently being evaluated for a possible malignancy.
- •Participant has any uncontrolled cardiovascular disease or has any clinically significant abnormal finding in ECG at Screening.
- •Participant has a history of trypanophobia, the extreme fear of medical procedures involving injections or needles, or who experiences vasovagal syncope and faints at the sight of blood or a needle.
- •Participant has a visible Panniculus on the abdomen in standing position.
- •Participant has severe abdominal visceral fat.
- •Participant has skin conditions, which would pose risk to the participant if receiving the IP or interfere with the safety or efficacy evaluation.
- •Participant has undergone the procedures at the treatment area that may affect IP administration.
- •Participant with contraindications to MRI imaging.
- •Participant is on prescription or over-the-counter weight reduction medication, weight reduction programs, or taking oral or injectable GLP-1 agonists.
- •Participant is undergoing long-term systemic steroid or immunosuppressive therapy which may affect the treatment area.
- •Participant is taking or will take any medication that is known strong inhibitor or inducer of CYP1A2 enzymes, sensitive CYP1A2 substrates, or medication with narrow therapeutic index.
- •Participant with history of hypersensitivity to local anesthesia.
- •Participant with known allergies or significant adverse reaction to the IP.
- •Participant with liver cirrhosis or abnormal liver function, or with any hepatic condition that interferes with the safety or efficacy assessments.
- •Participant with any renal impairment.
- •Participant has received any investigational product.
- •Participant considered to be unreliable or incapable of complying with the requirements of the protocol.
研究组 & 干预措施
CBL-514 injection
Experimental
Participants will receive CBL-514 administered up to 120 mL per treatment at a 4-weeks interval for up to 4 treatments.
干预措施: CBL-514 Injection (Drug)
Injectable 0.9% Sodium Chloride solution
Placebo Comparator
Participants will receive 0.9% Sodium Chloride administered up to 120 mL per treatment at a 4-week interval for up to 4 treatments.
干预措施: 0.9% Sodium Chloride (Drug)
结局指标
主要结局
Percentage of participants achieving at least a 2-grade improvement from baseline on Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) and a clinically meaningful reduction in abdominal fat.
时间窗: From baseline to 4 weeks after final treatment
Measured by a 5-point ordinal scale and MRI
次要结局
- Percentage change from baseline in abdominal fat in the CBL-514 group versus the placebo group.(From baseline to 4 weeks after final treatment)
- Percentage of participants with at least a 1-grade improvement on both Participant Reported Abdominal Fat Rating Scale (PR-AFRS) and Clinician Reported Abdominal Fat Rating Scale (CR-AFRS) in the CBL-514 group versus the placebo group.(From baseline to 4 weeks after final treatment)
研究者
研究点 (14)
Loading locations...
相似试验
尚未招募
3 期
A Phase 3 Trial of JKN2401 Injection in COPDNCT07330310Joincare Pharmaceutical Group Industry Co., Ltd888
招募中
2 期
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes MellitusNCT07282743Sun Pharmaceutical Industries Limited285
进行中（未招募）
2 期
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678Ascletis Pharma (China) Co., Limited100
尚未招募
3 期
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal PolyposisNCT07420257CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.212
招募中
3 期
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Cold UrticariaNCT07266402Celldex Therapeutics240